Skip to content

An injectable dynamic double-network hydrogel induces synergistic tumor pyroptosis and immune activation for potent anti-cancer immunity.

Nov 2026 · Journal of Controlled Release · pp. 115530 · 0 citations · 37 references
Medicine

Abstract

Hepatocellular carcinoma (HCC) remains a leading cause of cancer-related mortality, largely due to the limited efficacy of conventional systemic therapies. Herein, we report an injectable dynamic double-network hydrogel Gel@R/N, composed of poly(vinyl alcohol) and tannic acid crosslinked via dynamic boronate ester bonds, for the localized co-delivery of an immune adjuvant (R848) and a pyroptosis inducer (Nigericin) to achieve synergistic tumor ablation and immune activation. The self-healing capacity and pH-responsive drug release properties of this hydrogel enables precise intratumoral administration and sustained release within the acidic tumor microenvironment. Mechanistically, nigericin induces mitochondrial dysfunction and reactive oxygen species accumulation, thus activating the NLRP3/caspase-1/GSDMD pathway to trigger pyroptosis with a cell death rate of 26.4% alongside immunogenic cell death. The release of damage-associated molecular patterns (DAMPs) caused by pyroptosis, further promoted dendritic cell maturation to 20.8% and macrophage repolarization toward the pro-inflammatory M1 phenotype reaching 23.0%. Concurrently, R848 activates Toll-like receptor signaling to promote dendritic cell maturation and antigen presentation. Additionally, the hydrogel system effectively suppressed tumor growth in both subcutaneous and orthotopic hepatocellular carcinoma models, accompanied by a 1.55-fold increase in intratumoral CD8+ T cells infiltration and a 65.9% reduction in immunosuppressive cell populations. Overall, this work presents a safe and effective hydrogel-based platform for synergistic pyroptosis induction and immune activation, which offers a promising strategy for hepatocellular carcinoma immunity.

View source

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.